AKT1 and type 2 diabetes mellitus: In this research, a high-dose combination of DSW and fucoidan (H-CDF) mitigated T2DM symptoms in rats through the modulation of glycolipid levels, alleviation of hepatopancreatic pathology, and activation of the Akt/GSK-3β pathway.